Discovery of Novel Autotaxin Inhibitors Bearing the 4,5,6,7-Tetrahydro-7H-Pyrazolo[3,4-c]Pyridine-7-One Core for...

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Biochemistry

Background:

• Pulmonary fibrosis (PF) is a fatal, progressive lung disease.
• The autotaxin (ATX)-lysophosphatidic acid (LPA) signaling pathway is implicated in PF pathogenesis.
• Targeting ATX presents a potential therapeutic strategy for PF.

Purpose of the Study:

• To design novel autotaxin (ATX) inhibitors with improved pharmacological and physicochemical properties.
• To identify a new compound for potential pulmonary fibrosis (PF) therapy.

Main Methods:

• Design and synthesis of novel ATX inhibitors based on the PAT-409 scaffold.
• In vitro assessment of ATX inhibitory activity (IC50) and lipophilicity (cLogP).
• Molecular dynamics simulations to evaluate binding stability.
• Predictive analyses for drug-like properties and toxicity.

Main Results:

• Compound 19 demonstrated potent ATX inhibition (IC50 = 4.2 nM), surpassing PAT-409.
• Compound 19 exhibited significantly reduced lipophilicity (cLogP = 2.992) compared to PAT-409 (cLogP = 7.647).
• Molecular dynamics simulations confirmed stable binding of compound 19 to ATX.
• Predictive analyses indicated comparable safety and superior drug-like characteristics for compound 19.

Conclusions:

• Compound 19 is a highly promising ATX inhibitor with enhanced drug-like properties and safety.
• This novel compound represents a potential therapeutic candidate for pulmonary fibrosis (PF).
• Further development of compound 19 could lead to effective treatments for PF.